Building Billion-Dollar Businesses: An Interview with Robert Croce
Building a billion-dollar business in medical devices is rare enough; doing it twice is unheard of. In the course of a four-decade career, Bob Croce helped turn J&J into a giant in medical devices.
You may also be interested in...
Sensing a largely untapped opportunity in vascular closure, due to the drawbacks of manual compression and issues with first-generation products, device companies are working on newer-generation devices that both avoid the problems associated with the older devices and address the disadvantages of manual compression.
Late stent thrombosis (LST) concerns associated with drug-eluting stents (DES) dominated sessions at the 2006 Transcatheter Cardiovascular Therapeutics (TCT) annual conference, with additional long-term data presented on this topic. The general feeling expressed was one of relief that the expanded dataset presented at TCT showed the LST problem was not as bad as some had feared when the issue was discussed at the World Congress of Cardiology (WCC).
Most medical device start-ups seeking to tap into the enormous drug-eluting stent market have focused on novel stent or stent platform design, on the theory that drug efficacy is a given. But X-Cell Medical is betting that they've come up with a better drug. And they're making their case by stressing the importance of safety.